Efficacy and Safety of TPIAT for Resectable Adenocarcinoma of the Pancreas Region at High Risk of Postoperative Fistula

Efficacy and Safety of TPIAT for Resectable Adenocarcinoma of the Pancreas Region at High Risk of Postoperative Fistula is a phase 1/2, interventional study registered as NCT05116072 by University Hospital, Lille, with a registry enrolment figure of 36 participants, started 2022-02-20 and due to reach its primary completion in 2028-02-20. Interventions recorded: total pancreatectomy; intraportal islet autotransplantation. Conditions listed: Adenocarcinoma of the Pancreas; Adenocarcinoma of the Duodenum; Ampullary Adenocarcinoma. Primary outcome: the rate of patients who have completed the chemotherapy planned. Pancreatic eligibility wording from the registry: "Inclusion criteria are composed of preoperative conditions validated by intraoperative confirmation to plan an exit of the protocol if the pancreas does not finally appear with a high-risk of CR-POPF". Sites: France. No results are recorded here; the registry entry is the source.